Pirfenidone : A Promising Drug in Ocular Therapeutics
© 2024 Wiley-VHCA AG, Zurich, Switzerland..
Pirfenidone, initially indicated for lung fibrosis, has gone beyond its original purpose, and shown promise in eye care. This detailed review tracks its evolution from lung treatment to aiding eye healing as evidenced by published literature. Pirfenidone's multifaceted attributes extend to mitigating corneal fibrosis, inflammation, and trauma. Through rigorous investigations, its efficacy emerges in diabetic retinopathy, macular degeneration, and postoperative glaucoma interventions. As an unheralded protagonist, pirfenidone reshapes ocular care paradigms, inviting renewed research opportunities.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Chemistry & biodiversity - 21(2024), 3 vom: 22. März, Seite e202301389 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bisen, Amol Chhatrapati [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Corneal wound |
|---|
| Anmerkungen: |
Date Completed 18.03.2024 Date Revised 18.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cbdv.202301389 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367890623 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367890623 | ||
| 003 | DE-627 | ||
| 005 | 20240318234156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240201s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cbdv.202301389 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1334.xml |
| 035 | |a (DE-627)NLM367890623 | ||
| 035 | |a (NLM)38299764 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bisen, Amol Chhatrapati |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pirfenidone |b A Promising Drug in Ocular Therapeutics |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.03.2024 | ||
| 500 | |a Date Revised 18.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Wiley-VHCA AG, Zurich, Switzerland. | ||
| 520 | |a Pirfenidone, initially indicated for lung fibrosis, has gone beyond its original purpose, and shown promise in eye care. This detailed review tracks its evolution from lung treatment to aiding eye healing as evidenced by published literature. Pirfenidone's multifaceted attributes extend to mitigating corneal fibrosis, inflammation, and trauma. Through rigorous investigations, its efficacy emerges in diabetic retinopathy, macular degeneration, and postoperative glaucoma interventions. As an unheralded protagonist, pirfenidone reshapes ocular care paradigms, inviting renewed research opportunities | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Ophthalmology | |
| 650 | 4 | |a corneal wound | |
| 650 | 4 | |a keratitis | |
| 650 | 4 | |a ocular fibrosis | |
| 650 | 4 | |a patents | |
| 650 | 4 | |a proliferative vitreoretinopathy | |
| 650 | 7 | |a pirfenidone |2 NLM | |
| 650 | 7 | |a D7NLD2JX7U |2 NLM | |
| 650 | 7 | |a Pyridones |2 NLM | |
| 700 | 1 | |a Agrawal, Sristi |e verfasserin |4 aut | |
| 700 | 1 | |a Rayiti, Ramakrishna |e verfasserin |4 aut | |
| 700 | 1 | |a Sanap, Sachin Nashik |e verfasserin |4 aut | |
| 700 | 1 | |a Biswas, Arpon |e verfasserin |4 aut | |
| 700 | 1 | |a Mishra, Anjali |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Neeraj Mohan |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatta, Rabi Sankar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Chemistry & biodiversity |d 2004 |g 21(2024), 3 vom: 22. März, Seite e202301389 |w (DE-627)NLM167405101 |x 1612-1880 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2024 |g number:3 |g day:22 |g month:03 |g pages:e202301389 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cbdv.202301389 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2024 |e 3 |b 22 |c 03 |h e202301389 | ||